Posts tagged CAR-T
Ladenburg starts Bellicum Pharma at buy

Ladenburg Thalmann initiated coverage of Bellicum Pharmaceuticals (NASDAQ:BLCM) with a “buy” rating and $31 price target. The stock closed at $19.16 on Nov. 29.

Read More
Roth starts Sorrento Therapeutics at buy

Roth Capital Partners launched coverage of Sorrento Therapeutics (NASDAQ:SRNE) with a “buy” rating and $15 price target. The stock closed at $7.74 on Friday.

Sorrento has a proprietary fully human antibody library platform used to screen and identify highly specific monoclonal antibodies that can be used as therapeutic candidates. The company also has established an integrated network of subsidiaries and collaborations, with the idea to develop an extensive range of product candidates.

Read More